Hui Feng, MD, PhD
Associate Professor
Boston University School of Medicine
Dept of Pharmacology & Experimental Therapeutics

MD, Beijing Medical University
PhD, University of Georgia
MS, Peking Union Medical College




Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia, Neuroblastoma and Breast Cancer. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer cells with the genetic and imaging capacities of the zebrafish system.

Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify novel genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC.

The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.

Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences



2014-2017 St. Baldrick's Foundation: St. Baldrick Career Development Award
2013-2014 Karin Grunebaum Cancer Research Foundation: Grunebaum Faculty Fellowship
2013-2016 Boston University: Ralph Edwards Career Development Professorship
2012-2015 National Cancer Institute: Howard Temin Pathway to Independence Award in Cancer Research (R00)
2012-2013 American Cancer Society : American Cancer Society pilot Award
2009-2010 Stahl Family Charitable Foundation: Stahl Family Charitable Foundation Award
2009-2011 National Cancer Institute: Howard Temin Pathway to Independence Award in Cancer Research (K99)
2008 Harvard Partners in Health: Partners in Excellence Award
2005-2005 Cancer Research Institute: Postdoctoral Fellowship Award
2005 American Association for Cancer Research: American Association for Cancer Research Award - declined
2005-2008 Leukemia and Lymphoma Society: Special Fellow Award


The Role of DLST in Leukemogenesis
08/07/2018 - 07/31/2023 (PI)
NIH/National Cancer Institute
5R01CA215059-02

Regulatory Role and Targetability of UFDI in MYC-drlven Leukemia
01/01/2018 - 12/31/2021 (PI)
American Cancer Society, Inc.


Targeting DLST as a novel therapeutic approach for neuroblastoma
07/01/2018 - 06/30/2019 (PI)
St. Baldrick's Foundation


The Role of DLST in Leukemogenesis
08/15/2017 - 07/31/2018 (PI)
NIH/National Cancer Institute
1R56CA215059-01

Targeting DLST as a novel therapeutic approach for neuroblastoma
07/01/2017 - 06/30/2018 (PI)
St. Baldrick's Foundation


Targeting Elevated S1P1 Signaling as a Novel Therapeutic Approach for Triple-Negative Breast Cancer
07/01/2016 - 06/30/2018 (PI)
The Mary Kay Foundation


Targeting DLST as a Novel Therapeutic Approach for Neuroblastoma
07/01/2014 - 06/30/2017 (PI)
St. Baldrick's Foundation


Dissecting the regulatory role of DLST in MYC-driven Leukemogenesis
07/01/2015 - 12/31/2016 (PI)
Leukemia Research Foundation


Oncorequisite Genes in MYC-mediated Transformation
04/01/2012 - 03/31/2015 (PI)
NIH/National Cancer Institute
5R00CA134743-05



Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Qin X, Denton WD, Huiting LN, Smith KS, Feng H. Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity. Crit Rev Biochem Mol Biol. 2020 Jul 07; 1-32.View Related Profiles. PMID: 32633575
     
  2. Qin X, Laroche FFJ, Peerzade SAMA, Lam A, Sokolov I, Feng H. In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish. J Vis Exp. 2020 May 08; (159).View Related Profiles. PMID: 32449736
     
  3. Igwebuike C, Yaglom J, Huiting L, Feng H, Campbell JD, Wang Z, Havasi A, Pimentel D, Sherman MY, Borkan SC. Cross organelle stress response disruption promotes gentamicin-induced proteotoxicity. Cell Death Dis. 2020 Apr 03; 11(4):217.View Related Profiles. PMID: 32245975
     
  4. Wong CK, Lambert AW, Ozturk S, Papageorgis P, Lopez D, Shen N, Sen Z, Abdolmaleky HM, Gyorffy B, Feng H, Thiagalingam S. Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. Mol Cancer Res. 2020 03; 18(3):414-423.View Related Profiles. PMID: 31932471
     
  5. Peng B, Almeqdadi M, Laroche F, Palantavida S, Dokukin M, Roper J, Yilmaz OH, Feng H, Sokolov I. Data on ultrabright fluorescent cellulose acetate nanoparticles for imaging tumors through systemic and topical applications. Data Brief. 2019 Feb; 22:383-391. PMID: 30596135; DOI: 10.1016/j.dib.2018.12.030;
     
  6. Su H, Hu J, Huang L, Yang Y, Thenoz M, Kuchmiy A, Hu Y, Li P, Feng H, Zhou Y, Taghon T, Van Vlierberghe P, Qing G, Chen Z, Liu H. SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival. Nat Commun. 2018 10 15; 9(1):4281. PMID: 30323192; DOI: 10.1038/s41467-018-06523-4;
     
  7. Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA. Functional and genomic analyses reveal therapeutic potential of targeting ß-catenin/CBP activity in head and neck cancer. Genome Med. 2018 07 20; 10(1):54.View Related Profiles. PMID: 30029671
     
  8. Narasimhan S, Stanford Zulick E, Novikov O, Parks AJ, Schlezinger JJ, Wang Z, Laroche F, Feng H, Mulas F, Monti S, Sherr DH. Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. Int J Mol Sci. 2018 May 07; 19(5).View Related Profiles. PMID: 29735912
     
  9. Huiting LN, Samaha Y, Zhang GL, Roderick JE, Li B, Anderson NM, Wang YW, Wang L, Laroche F, Choi JW, Liu CT, Kelliher MA, Feng H. UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response. Leukemia. 2018 11; 32(11):2339-2351.View Related Profiles. PMID: 29743725; DOI: 10.1038/s41375-018-0141-x;
     
  10. Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018 02; 9(2):216-237.View Related Profiles. PMID: 28748451
     
Showing 10 of 33 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 33 publications over 15 distinct years, with a maximum of 5 publications in 2016 and 2018

YearPublications
19991
20032
20051
20072
20091
20102
20111
20122
20131
20141
20153
20165
20172
20185
20204
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Cancer
Cancer Therapeutics
MYC
Tumor Intravasation
Zebrafish

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Education Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:

72 E. Concord St Silvio Conte (K)
Boston MA 02118
Google Map


Feng's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department